Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS

• Vittorio Stefoni,
• Miriam Marangon,
• Alessandro Re,
• Arben Lleshi,
• Maurizio Bonfichi,
• Antonello Pinto,
• Nicola Bianchetti,
• Cinzia Pellegrini,
• Lisa Argnani,
• Pier Luigi Zinzani

Affiliations

Vittorio Stefoni

Institute of Hematology L. e A. Seràgnoli, University of Bologna, Bologna, Italy;

Miriam Marangon

Institute of Hematology L. e A. Seràgnoli, University of Bologna, Bologna, Italy;

Alessandro Re

Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy;

Arben Lleshi

National Cancer Institute, Aviano, Italy;

Maurizio Bonfichi

Division of Hematology, IRCCS Policlinico San Matteo, Pavia, Italy;

Antonello Pinto

National Cancer Institute, Fondazione Pascale, IRCCS, Napoli, Italy;

Nicola Bianchetti

Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy;

Cinzia Pellegrini

Institute of Hematology L. e A. Seràgnoli University of Bologna, Bologna, Italy

Lisa Argnani

Institute of Hematology L. e A. Seràgnoli, University of Bologna, Bologna, Italy;

Pier Luigi Zinzani

Institute of Hematology L. e A. Seràgnoli University of Bologna, Bologna, Italy